BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20050931)

  • 21. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
    Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
    J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Digesting the doughnut hole.
    Joyce GF; Zissimopoulos J; Goldman DP
    J Health Econ; 2013 Dec; 32(6):1345-55. PubMed ID: 24308883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
    Park T; Jung J
    J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicare essential: an option to promote better care and curb spending growth.
    Davis K; Schoen C; Guterman S
    Health Aff (Millwood); 2013 May; 32(5):900-9. PubMed ID: 23650323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of the coverage gap on drug spending: a closer look at Medicare Part D.
    Zhang Y; Donohue JM; Newhouse JP; Lave JR
    Health Aff (Millwood); 2009; 28(2):w317-25. PubMed ID: 19189991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
    McWilliams JM; Zaslavsky AM; Huskamp HA
    JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
    Bonakdar Tehrani A; Cunningham PJ
    Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
    Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
    Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries.
    Zhang Y; Lave JR; Newhouse JP; Donohue JM
    J Gerontol B Psychol Sci Soc Sci; 2010 Jul; 65(4):502-7. PubMed ID: 20008482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
    Glynn A; Hernandez I; Roberts ET
    Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
    Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
    J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
    Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
    J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the impact of coverage gaps in the Medicare Part D drug benefit.
    Hudson N
    Find Brief; 2008 Apr; 11(3):1-3. PubMed ID: 18441611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.